Last reviewed · How we verify
vildagliptin + acarbose
vildagliptin + acarbose is a DPP-4 inhibitor + alpha-glucosidase inhibitor Small molecule drug developed by Radboud University Medical Center. It is currently in Phase 3 development for Type 2 diabetes mellitus.
Vildagliptin and acarbose work together to improve blood glucose control by enhancing insulin secretion and reducing carbohydrate absorption.
Vildagliptin is a small molecule that works as a dipeptidyl peptidase-4 (DPP-4) inhibitor, according to ChEMBL. Vildagliptin in combination with acarbose has been studied in clinical trials for conditions such as type 2 diabetes and obesity, including a trial examining its effect on visceral fat distribution in newly diagnosed type 2 diabetes patients.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | vildagliptin + acarbose |
|---|---|
| Sponsor | Radboud University Medical Center |
| Drug class | DPP-4 inhibitor + alpha-glucosidase inhibitor |
| Target | DPP-4, alpha-glucosidase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Vildagliptin inhibits DPP-4, which increases levels of GLP-1 and GIP, leading to enhanced insulin secretion. Acarbose inhibits alpha-glucosidase enzymes in the small intestine, slowing down the breakdown of carbohydrates and reducing postprandial glucose spikes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal symptoms (e.g., diarrhea, flatulence)
Key clinical trials
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients (PHASE4)
- Incretin-based Drugs and Acute Pancreatitis
- Incretin-based Drugs and the Risk of Heart Failure
- Incretin-based Drugs and Pancreatic Cancer
- Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes (PHASE3)
- Vildagliptin and Endothelium-dependent Vasodilatation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- vildagliptin + acarbose CI brief — competitive landscape report
- vildagliptin + acarbose updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI
Frequently asked questions about vildagliptin + acarbose
What is vildagliptin + acarbose?
How does vildagliptin + acarbose work?
What is vildagliptin + acarbose used for?
Who makes vildagliptin + acarbose?
What drug class is vildagliptin + acarbose in?
What development phase is vildagliptin + acarbose in?
What are the side effects of vildagliptin + acarbose?
What does vildagliptin + acarbose target?
Related
- Drug class: All DPP-4 inhibitor + alpha-glucosidase inhibitor drugs
- Target: All drugs targeting DPP-4, alpha-glucosidase
- Manufacturer: Radboud University Medical Center — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing